StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$196.79−10.01 (-4.84%)

Close on Nov 18, 2026Market cap $78.57BP/E –Yield –

Earnings

Moderna's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 12, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.30B
+30.0% on a year earlier
EPS, Q3 FY2026
$0.38
-$0.51 a year earlier
Latest guidance
Raised
Nov 6, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Moderna's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 12, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 6, 2026before the open$1.30B+30.0%$0.38Release
Q2 FY2026ended Jun 30, 2026Jul 31, 2026before the open$145.00M+2.1%-$1.97Release
Q1 FY2026ended Mar 31, 2026May 1, 2026before the open$389.00M+260.2%-$3.40Release
Q4 FY2025ended Dec 31, 2025Feb 13, 2026before the open$678.00M-32.2%-$2.11Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$1.00B-47.4%-$0.51Release
Q2 FY2025ended Jun 30, 2025Aug 1, 2025before the open$142.00M-41.1%-$2.13Release
Q1 FY2025ended Mar 31, 2025May 1, 2025before the open$108.00M-35.3%-$2.52Release
Q4 FY2024ended Dec 31, 2024Feb 14, 2025before the open$1.00B-64.3%-$2.91Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$1.90B+5.6%$0.03Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$241.00M-29.9%-$3.33Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$167.00M-91.2%-$3.07Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Moderna's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenue growthFY2026+10%+10%ReaffirmedJul 31, 2026
total revenue growthFY2026+15% – +25%+10%RaisedNov 6, 2026
Capital expendituresFY2026$200.00M$200.00M – $300.00MLoweredNov 6, 2026
Capital expendituresFY2026$200.00M – $300.00M$200.00M – $300.00MReaffirmedJul 31, 2026
cash and investmentsFY2026$8.10B – $8.30B–RaisedNov 6, 2026
Cost of salesFY2026$1.70B$900.00MLoweredNov 6, 2026
Cost of salesFY2026$1.70B$1.80BLoweredJul 31, 2026
estimated GAAP operating costsGAAPFY2026$5.40B – $5.70B–NewMay 1, 2025
GAAP operating expensesGAAPFY2026$4.90B–NewJan 12, 2026
potential cash cost savingsFY2026$500.00M–NewJan 13, 2025
Research and development expensesFY2026$2.70B$3.00BRaisedNov 6, 2026
Research and development expensesFY2026$2.90B$3.00BRaisedJul 31, 2026
Selling, general and administrative expensesFY2026$1.00B$1.00BLoweredNov 6, 2026
Selling, general and administrative expensesFY2026$1.00B$1.00BLoweredJul 31, 2026
Year-end cash and investmentsFY2026$4.70B – $5.20B$4.50B – $5.00BRaisedJul 31, 2026
Year-end cash and investmentsFY2026$5.50B – $6.00B–RaisedFeb 13, 2026
annual salesFY2027$8.00B – $15.00B–NewMay 4, 2023
GAAP operating cost estimateGAAPFY2027$4.70B – $5.00B–NewMay 1, 2025
GAAP operating expensesGAAPFY2027$4.20B – $4.60B–NewJan 12, 2026

Guidance vs results

The last range Moderna gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$1.90B$1.93BΣ4QAbove range
Q2 FY2023Revenue$200.00M – $300.00M$344.00MAbove range

Guidance history

Every forecast Moderna put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 6, 2026Capital expendituresFY2026$200.00MLowered
Nov 6, 2026Cost of salesFY2026$1.70BLowered
Nov 6, 2026Research and development expensesFY2026$2.70BRaised
Nov 6, 2026Selling, general and administrative expensesFY2026$1.00BLowered
Nov 6, 2026cash and investmentsFY2026$8.10B – $8.30BRaised
Nov 6, 2026total revenue growthFY2026+15% – +25%Raised
Jul 31, 2026Capital expendituresFY2026$200.00M – $300.00MReaffirmed
Jul 31, 2026Cost of salesFY2026$1.70BLowered
Jul 31, 2026Research and development expensesFY2026$2.90BRaised
Jul 31, 2026Selling, general and administrative expensesFY2026$1.00BLowered
Jul 31, 2026Year-end cash and investmentsFY2026$4.70B – $5.20BRaised
Jul 31, 2026revenue growthFY2026+10%Reaffirmed
May 1, 2026Capital expendituresFY2026$200.00M – $300.00MNew
May 1, 2026Cost of salesFY2026$1.80BNew
May 1, 2026Research and development expensesFY2026$3.00BRaised
May 1, 2026Selling, general and administrative expensesFY2026$1.00BLowered
May 1, 2026Year-end cash and investmentsFY2026$4.50B – $5.00BRaised
May 1, 2026revenue growthFY2026+10%Reaffirmed
Feb 13, 2026Capital expendituresFY2026$200.00M – $300.00MNew
Feb 13, 2026Cost of salesFY2026$900.00MRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Moderna filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. News
  4. News
  5. Results
  6. Update
  7. Results
  8. Results
  9. Update
  10. Results
  11. Update
  12. Update
  13. Results
  14. Results
  15. Results

See a number that looks wrong?